In a phase I trial led by Dr. Vinod Balachandran at the Memorial Sloan Kettering Cancer Center, this vaccine, combined with atezolizumab and mFOLFIRINOX chemotherapy (PD-L1 inhibitors), elicited robust T-cell responses in 50% of participants, with responders showing prolonged recurrence-free survival, in some exceeding three years post-treatment [84]. This evidence concerns the gene CD274 and cancer.